Related Experiment Video

Updated: Dec 12, 2025

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.6K

Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors

Toni K Choueiri1

  • 1Harvard Medical School, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Lank Center for Genitourinary Oncology, 44 Binney Street, dana 1230, Boston, MA 02115, USA. Toni_Choueiri@dfci.harvard.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|June 3, 2008
PubMed

Insights

Axitinib, an inhibitor of VEGF and PDGF, shows activity in various solid tumors like thyroid and lung cancer. While side effects occurred, the drug was generally well-tolerated in Phase II trials.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Axitinib is an oral tyrosine kinase inhibitor targeting VEGF, PDGF, and CSF-1R.
  • It is under development by Pfizer Inc. for various solid tumors.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of axitinib in Phase II trials.
  • To assess axitinib's activity as a monotherapy and in combination with chemotherapy.

Main Methods:

  • Phase II clinical trials were conducted.
  • Axitinib was administered alone or combined with chemotherapeutic agents.

Main Results:

  • Activity was observed in thyroid, pancreatic, lung, renal, breast, and colorectal cancers, as well as melanoma and other carcinomas.
  • Common side effects included fatigue, hypertension, diarrhea, hand-foot syndrome, and proteinuria.
  • Axitinib was generally well-tolerated.

Conclusions:

  • Axitinib demonstrates potential therapeutic activity across a range of solid tumors.
  • Further investigation in larger, randomized Phase II/III studies is warranted.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.2K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
422
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K